Document is current

Article History

Received: 18 December 2020

Accepted: 23 May 2021

First Online: 7 June 2021

Declarations

:

: The REMARRY and PURSUIT trials are conducted in accordance with the Declaration of Helsinki, the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects, and the Clinical Trial Acts in Japan. Each trial has been approved by the institutional review board of each participating institution and National Cancer Center Hospital East Certified Review Board, respectively. Written informed consent shall be obtained from all patients before enrollment.

: Not applicable.

: DK reports honoraria from Takeda, Chugai, Lilly, Merck Serono, Taiho, Ono, Bristol-Myers Squibb, and Sysmex. HB reports research funding from AstraZeneca and Sysmex and honoraria from Taiho and Lilly. TK reports honoria from Bayer, Chugai, Yakult Honsha, Sanofi, Lilly, Taiho, Takeda, Merck. EO reports honoraria from Taiho, Yakult Honsha, Merck Biopharma, Bayer, Lilly, Ono, Takeda, and Chugai. YN reports research funding from Taiho, Guardant Health, Genomedia, and Chugai. ES reports honoraria from Taiho, Chugai, Takeda, Merck Biopharma, Lilly, Sanofi, and Daiichi-Sankyo. YS reports research funding from Taiho, Takeda, Chugai, Lilly, Daiichi-Sankyo, Merck Serono, and Sanofi and honoraria from Taiho, Chugai, Takeda, Yakult Honsha, Sanofi, Bayer, Bristol Myers Squib, Merck Biopharma, Lilly, Nippon Kayaku, and Kyowa Hakko Kirin and a consulting or advisory role for Takeda and Daiichi-Sankyo. KY reports research funding from Taiho and honoraria from Daiichi-Sankyo, Lilly, Yakult Honsha, Merck Serono, Bristol Myers Squibb, Ono, MSD, Sanofi, Chugai, Takeda, Bayer, and Taiho. SY reports honoraria from Taiho, Ono, Sanofi, Bayer, Lilly, Bristol-Myers Squibb, Merck Biopharma, Chugai, Yakult Honsha, and MSD. TY1 reports research funding from Chugai, Takeda, Taiho, Daiichi Sankyo, Ono, Boehringer Ingelheim, Bayer, Merck Serono, Astellas, and Lilly and honoraria from Chugai, Takeda, Taiho, Boehringer Ingelheim, Bayer, and Pfizer; fees for consultancy from Gilead Sciences, Daiichi-Sankyo, HUYA Biosciences, and Sysmex. TY2 reports research funding from Taiho, Ono, Amgen, Parexel International, MSD, Chugai, Daiichi-Sankyo, Sumitomo Dainippon, and Sanofi and honoraria from Taiho, Takeda, Chugai, Lilly, Bayer, and Merck Biopharma. HT reports research funding from Daiichi-Sankyo, Takeda, Dainippon Sumitomo Pharma, Array BioPharma, Sysmex, MSD Oncology, Ono, and Novartis and honoraria from Mitsubishi Tanabe Pharma, Nippon Kayaku, Takeda, Taiho, Yakult Honsha, Bayer, Merck Serono, Bristol-Myers Squibb, Daiichi-Sankyo, Chugai, Sanofi, MSD, Lilly, Medical & Biological Laboratories Co Ltd., and Novartis.YK reports research funding from Takeda and honoraria from Bayer, Chugai, Yakult Honsha, Sanofi, Lilly, Taiho, Takeda, Merck and Sysmex. The remaining authors have declared no conflicts of interest.